FI912623A - Farmakologiskt aktiva foereningar med verkan pao det centrala nervsystemet. - Google Patents

Farmakologiskt aktiva foereningar med verkan pao det centrala nervsystemet. Download PDF

Info

Publication number
FI912623A
FI912623A FI912623A FI912623A FI912623A FI 912623 A FI912623 A FI 912623A FI 912623 A FI912623 A FI 912623A FI 912623 A FI912623 A FI 912623A FI 912623 A FI912623 A FI 912623A
Authority
FI
Finland
Prior art keywords
hydrogen
halo
alkyl
central network
nitro
Prior art date
Application number
FI912623A
Other languages
English (en)
Other versions
FI912623A0 (fi
Inventor
Michael John Leach
Malcolm Stuart Nobbs
Ramachandran Iyer
Clive Leonard Yeates
Philip Alan Skone
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of FI912623A0 publication Critical patent/FI912623A0/fi
Publication of FI912623A publication Critical patent/FI912623A/fi
Priority to FI961410A priority Critical patent/FI961410A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Paper (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI912623A 1990-06-01 1991-05-31 Farmakologiskt aktiva foereningar med verkan pao det centrala nervsystemet. FI912623A (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI961410A FI961410A0 (fi) 1990-06-01 1996-03-28 Farmakologisesti aktiivisia keskushermostoon vaikuttavia yhdisteitä

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909012316A GB9012316D0 (en) 1990-06-01 1990-06-01 Pharmacologically active cns compounds

Publications (2)

Publication Number Publication Date
FI912623A0 FI912623A0 (fi) 1991-05-31
FI912623A true FI912623A (fi) 1991-12-02

Family

ID=10676964

Family Applications (1)

Application Number Title Priority Date Filing Date
FI912623A FI912623A (fi) 1990-06-01 1991-05-31 Farmakologiskt aktiva foereningar med verkan pao det centrala nervsystemet.

Country Status (25)

Country Link
EP (2) EP0679645A1 (fi)
JP (1) JPH06340634A (fi)
KR (1) KR920000733A (fi)
AT (1) ATE141263T1 (fi)
AU (2) AU652753B2 (fi)
CA (1) CA2043640A1 (fi)
CZ (1) CZ281070B6 (fi)
DE (1) DE69121317T2 (fi)
DK (1) DK0459819T3 (fi)
ES (1) ES2093078T3 (fi)
FI (1) FI912623A (fi)
GB (1) GB9012316D0 (fi)
GR (1) GR3021237T3 (fi)
HU (2) HUT58707A (fi)
IE (1) IE911861A1 (fi)
IL (2) IL113599A (fi)
MY (2) MY109958A (fi)
NO (1) NO180375C (fi)
NZ (3) NZ272001A (fi)
PL (2) PL170373B1 (fi)
PT (1) PT97827B (fi)
RU (1) RU2091374C1 (fi)
SK (1) SK278444B6 (fi)
TW (1) TW224460B (fi)
ZA (1) ZA914165B (fi)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
PL169106B1 (pl) * 1991-01-30 1996-06-28 Wellcome Found Sposób wytwarzania dyspergowalnej w wodzie tabletki PL PL PL PL PL PL PL
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
GB9226377D0 (en) * 1992-12-18 1993-02-10 Babbedge Rachel C Pharmaceutical compositions
AU5704594A (en) * 1992-12-18 1994-07-19 Wellcome Foundation Limited, The Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9319341D0 (en) * 1993-09-17 1993-11-03 Wellcome Found Novel process
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
CN102584799A (zh) 1999-09-16 2012-07-18 田边三菱制药株式会社 含氮的6-员芳香环化合物
CN1657523A (zh) 2000-04-28 2005-08-24 田边制药株式会社 环状化合物
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
JP5154728B2 (ja) * 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ，インコーポレイテッド 神経栄養活性を有する置換５−アルキニルピリミジン
CN1503797A (zh) 2001-02-26 2004-06-09 田边制药株式会社 吡啶并嘧啶或二氮杂萘衍生物
BR0307429A (pt) * 2002-02-05 2004-12-28 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
CN103110635A (zh) 2005-07-04 2013-05-22 海波因特制药有限责任公司 组胺h3受体拮抗剂
EP2038256A1 (en) 2006-05-23 2009-03-25 TransTech Pharma, Inc 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ']-bipyridine and its use as a medicament
EA016026B1 (ru) 2006-05-29 2012-01-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи 3-(1,3-бензодиоксол-5-ил)-6-(4-циклопропилпиперазин-1-ил)пиридазин, его соли и сольваты и его применение в качестве антагониста н3 рецептора гистамина
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
MX354412B (es) 2011-06-10 2018-03-05 Merck Patent Gmbh Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton.
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP3094627B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
PL3468972T3 (pl) 2016-06-14 2020-11-16 Novartis Ag Związki i kompozycje do hamowania aktywności shp2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE518622A (fi) *
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds

Also Published As

Publication number Publication date
PT97827B (pt) 1998-10-30
HU911826D0 (en) 1991-12-30
HUT58707A (en) 1992-03-30
IL113599A (en) 1997-09-30
HU211649A9 (en) 1995-12-28
DE69121317D1 (de) 1996-09-19
IL98330A (en) 1996-10-31
AU652753B2 (en) 1994-09-08
CZ281070B6 (cs) 1996-06-12
GB9012316D0 (en) 1990-07-18
RU2091374C1 (ru) 1997-09-27
GR3021237T3 (en) 1997-01-31
FI912623A0 (fi) 1991-05-31
ZA914165B (en) 1993-03-01
AU7809791A (en) 1991-12-05
EP0679645A1 (en) 1995-11-02
EP0459819A3 (en) 1992-03-11
NO180375B (no) 1996-12-30
NZ272001A (en) 1997-03-24
PL166656B1 (pl) 1995-06-30
NZ238360A (en) 1997-03-24
IE911861A1 (en) 1991-12-04
TW224460B (fi) 1994-06-01
PL170373B1 (pl) 1996-12-31
NO912100D0 (no) 1991-05-31
DE69121317T2 (de) 1997-01-02
AU6745594A (en) 1994-09-15
NO180375C (no) 1997-04-09
JPH06340634A (ja) 1994-12-13
CA2043640A1 (en) 1991-12-02
ATE141263T1 (de) 1996-08-15
CS164391A3 (en) 1992-02-19
DK0459819T3 (da) 1996-09-02
EP0459819B1 (en) 1996-08-14
NO912100L (no) 1991-12-02
AU680252B2 (en) 1997-07-24
EP0459819A2 (en) 1991-12-04
IL113599A0 (en) 1995-08-31
MY109958A (en) 1997-10-31
IL98330A0 (en) 1992-06-21
ES2093078T3 (es) 1996-12-16
NZ248501A (en) 1997-03-24
KR920000733A (ko) 1992-01-29
PT97827A (pt) 1992-03-31
SK278444B6 (en) 1997-05-07
MY136248A (en) 2008-08-29

Similar Documents

Publication Publication Date Title
FI912623A0 (fi) Farmakologiskt aktiva foereningar med verkan pao det centrala nervsystemet.
HUP9901113A1 (hu) Herbicid hatású és növényi növekedést szabályozó hatású 2-amino-4-biciklo-amino-1,3,5-triazinok
FI89709B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara arylderivat
ES2162623T3 (es) Derivados fenilicos trisustituidos como inhibidores de fosfodiesterasa y procedimientos para su preparacion.
BG95818A (en) Herbicides
ES8503342A1 (es) Procedimiento para la preparacion de n-heterociclosulfonil-n'-pirimidinil-y-triacinil-ureas.
NO972666L (no) Anilinderivater med nitrogenmonoksyd-synteseinhiberende aktivitet
IE811580L (en) Herbicidal compounds
HUP9801057A2 (hu) Piridil-tiazol-származékok és mikroorganizmusok elleni növényvédő szerként történő alkalmazásuk
YU165791A (sh) Postupak za pripremanje derivata 8-hlorohinolona
ATE84028T1 (de) Biologisch aktive verbindungen.
FI902775A0 (fi) Aryloxi-, aryltio-, heteroaryloxi-, heteroaryltio-alkylenderivat av aminer.
DK182181A (da) Antihypertensivt virksomme lactamer og fremgangsmaade til fremstilling heraf
DE3671623D1 (de) Diphenyletherherbizide.
NO954109L (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte 5-arylpyrimidiner
TH11828EX (th) สารประกอบต่าง ๆ ที่เกี่ยวกับ cns ซึ่งออกฤทธิ์ทางเภสัชวิทยา
ES8604535A1 (es) Un procedimiento para la preparacion de derivados heteroci- clicos de la urea

Legal Events

Date Code Title Description
FD Application lapsed